Only about half of US teen girls have been vaccinated against the forms of human papillomavirus (HPV) that are associated […]
People who are at high risk of cancer as a result of their family history may be advised to undergo […]
A test for high-risk types of human papillomavirus (HPV) is better than the Pap test at detecting cervical cancer. In […]
A new human papillomavirus (HPV) test—intended to detect women at highest risk of serious cervical abnormalities—has been approved by the […]
The lung cancer death rate among women appears to be declining for the first time in 40 years, according to […]
Persistent infection with a high-risk type of human papillomavirus (HPV) is the principal cause of cervical cancer, and HPV testing […]
Results from a recent international study indicate that the vaccine Gardasil® (quadrivalent human papillomavirus [types 6, 11, 16, 18] recombinant […]
Apparently, old habits die hard: less than one-third of physicians report compliance with the updated guidelines for cervical cancer screening […]
You may have heard about HPV’s role in cervical cancer, but what about head and neck cancer? By Kari Bohlke, […]
More than half of young adults in a new sexual relationship are infected with human papillomavirus (HPV), and of those […]
Women over the age of 40 are not likely to benefit from a vaccine designed to prevent human papillomavirus (HPV), according to the results of a study published in the Journal of the National Cancer Institute.1 HPV has been shown to cause cervical cancer.
Cervarix®—a vaccine that reduces the risk of cervical cancer by protecting against two high-risk types of human papillomavirus (HPV)—remains effective for more than six years. These results were published in the Lancet.
As the month of January brings cervical cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated cervical cancer information throughout the year.
The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.
The U.S. Food and Drug Administration has approved Cervarix®, a vaccine against two high-risk types of human papillomavirus (HPV), for […]
A U.S. Food and Drug Administration (FDA) advisory committee has concluded that Cervarix®—a vaccine against two high-risk types of human papillomavirus (HPV)—is safe and effective for the prevention of cervical cancer.
A vaccine against two high-risk types of human papillomavirus (HPV) reduced the risk of precancerous cervical changes in young women. These results were published in The Lancet.
Cervical intraepithelial neoplasia increases risk for invasive cervical cancer.